→ Ultimate Under-the-Radar Stock (From Trending Stock News Report)
Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) – Oppenheimer reduced their Q4 2024 earnings per share (EPS) estimates for Prestige Consumer Healthcare in a note issued to investors on Friday, February 17th. Oppenheimer analyst R. Parikh now forecasts that the company will post earnings per share of $1.11 for the quarter, down from their prior forecast of $1.13. Oppenheimer has a “Outperform” rating and a $72.00 price objective on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.25 per share. Oppenheimer also issued estimates for Prestige Consumer Healthcare’s FY2025 earnings at $4.65 EPS.
Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last announced its quarterly earnings data on Thursday, February 2nd. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. Prestige Consumer Healthcare had a net margin of 18.97% and a return on equity of 12.65%. The business had revenue of $275.50 million during the quarter, compared to the consensus estimate of $273.84 million. During the same quarter last year, the firm earned $0.99 earnings per share. The firm’s quarterly revenue was up .4% compared to the same quarter last year.
A number of other brokerages have also weighed in on PBH. Canaccord Genuity Group started coverage on shares of Prestige Consumer Healthcare in a report on Thursday, November 17th. They set a “buy” rating and a $71.00 price objective on the stock. Canaccord Genuity Group began coverage on shares of Prestige Consumer Healthcare in a research report on Wednesday, November 16th. They set a “buy” rating and a $71.00 price target for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $71.00.
Prestige Consumer Healthcare Stock Performance
Shares of NYSE:PBH opened at $61.47 on Monday. The firm has a 50 day moving average of $63.34 and a 200 day moving average of $57.78. The company has a quick ratio of 1.56, a current ratio of 2.55 and a debt-to-equity ratio of 0.85. Prestige Consumer Healthcare has a 52 week low of $48.51 and a 52 week high of $67.45. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of 14.74, a price-to-earnings-growth ratio of 1.81 and a beta of 0.60.
Institutional Trading of Prestige Consumer Healthcare
Several hedge funds and other institutional investors have recently made changes to their positions in PBH. Versant Capital Management Inc grew its holdings in Prestige Consumer Healthcare by 38.1% in the third quarter. Versant Capital Management Inc now owns 587 shares of the company’s stock valued at $29,000 after purchasing an additional 162 shares during the period. Centiva Capital LP raised its holdings in shares of Prestige Consumer Healthcare by 4.2% during the fourth quarter. Centiva Capital LP now owns 4,174 shares of the company’s stock worth $261,000 after purchasing an additional 167 shares during the period. Meritage Portfolio Management raised its holdings in shares of Prestige Consumer Healthcare by 2.5% during the fourth quarter. Meritage Portfolio Management now owns 7,061 shares of the company’s stock worth $442,000 after purchasing an additional 169 shares during the period. Meeder Asset Management Inc. grew its position in shares of Prestige Consumer Healthcare by 79.0% during the second quarter. Meeder Asset Management Inc. now owns 451 shares of the company’s stock worth $27,000 after acquiring an additional 199 shares during the last quarter. Finally, Okabena Investment Services Inc. grew its position in shares of Prestige Consumer Healthcare by 10.9% during the second quarter. Okabena Investment Services Inc. now owns 2,089 shares of the company’s stock worth $123,000 after acquiring an additional 205 shares during the last quarter. Institutional investors and hedge funds own 99.98% of the company’s stock.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Prestige Consumer Healthcare, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Prestige Consumer Healthcare wasn’t on the list.
While Prestige Consumer Healthcare currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
link